Refine
Has Fulltext
- yes (45)
Is part of the Bibliography
- yes (45)
Year of publication
Document Type
- Journal article (45)
Language
- English (45)
Keywords
- psoriasis (4)
- Merkel cell carcinoma (3)
- immunohistochemistry (3)
- therapy (3)
- COVID-19 (2)
- Germany (2)
- PD-L1 (2)
- T cells (2)
- bullous pemphigoid (2)
- dermatology (2)
- inflammation (2)
- melanoma (2)
- B cells (1)
- B-cell lymphoma (1)
- B-cells (1)
- B7-H1 Antigen (1)
- CD10 (1)
- CD274 (1)
- CD30 (1)
- CD8(+) (1)
- CTLA-4 Antigen (1)
- Clinical trials (1)
- Crohn disease (1)
- Cutaneous lymphoma (1)
- Cutaneous metastatic Crohn’s disease (1)
- Cx43 (1)
- Drug Therapy, Combination (1)
- EBER in situ hybridization (1)
- ERBB receptors (1)
- EVER1 (1)
- EVER2 (1)
- Epigenetic regulation (1)
- FoxO3 (1)
- HDAC (1)
- Histone deacetylase (1)
- Human papillomavirus (1)
- IFN (1)
- Immune-related adverse event (1)
- Ipilimumab (1)
- JAK2 (1)
- Kaposi sarcoma (1)
- Kerinokeratosis papulosa (1)
- LRIG1 (1)
- LSD1 (1)
- Lysine-specific methylase (1)
- MTB (1)
- Melanoma (1)
- Minimal change disease (1)
- Molecular imaging (1)
- Mycobacterium marinum (1)
- Nfatc1 (1)
- Nivolumab (1)
- PD-1 (1)
- PEComa (1)
- PRAME (1)
- Positron emission tomography (1)
- Programmed Cell Death 1 Receptor (1)
- RNA probe (1)
- S2k guidelines (1)
- SARS-CoV-2 (1)
- Skin (1)
- Skin Neoplasms (1)
- Somatostatin receptor expression (1)
- T-antigens (1)
- TP53 (1)
- TRRAP (1)
- Th17 (1)
- Tregs (1)
- Tubulin (1)
- United States (1)
- Waxy papulosis of childhood (1)
- acitretin (1)
- adverse event (1)
- allergies (1)
- allergy (1)
- aluminum granuloma (1)
- antitumor immunity (1)
- autoimmune disease (1)
- autoimmune diseases (1)
- autoimmune skin blistering disease (1)
- avelumab (1)
- biologics (1)
- biomarker (1)
- breast cancer (1)
- cancer care (1)
- cancer microenvironment (1)
- cell membranes (1)
- cell rich blue nevus (1)
- cell staining (1)
- chemokine (1)
- cicatricial pemphigoid (1)
- classification (1)
- combination (1)
- common blue nevus (1)
- comorbid diseases (1)
- comorbidity (1)
- cutaneous PEComa (1)
- cutaneous T-cell-lymphoma (1)
- cutaneous adverse events (1)
- cutaneous angiosarcoma (1)
- cutaneous lupus erythematosus (1)
- cutaneous lymphomas (1)
- diagnosis (1)
- differential gene expression (1)
- disease severity (1)
- drug therapy (1)
- drug-induced liver injury (DILI) (1)
- endemic pemphigus foliaceus (1)
- environmental factors (1)
- eosinophils (1)
- experience (1)
- fatty liver disease (1)
- genetic association (1)
- health economics (1)
- health insurance (1)
- health-care costs (1)
- hemangioma (1)
- histologic findings (1)
- immune cell infiltration (1)
- immunology (1)
- immunotherapy (1)
- improvement (1)
- indirect costs (1)
- inflammatory disease (1)
- inpatients (1)
- interferon-\(\beta\) (1)
- interleukins (1)
- ipilimumab (1)
- keratinocytes (1)
- laminin 332 (1)
- large cell transformation (1)
- leg cramps (1)
- lesions (1)
- lichen planus (1)
- life (1)
- long-term outcome (1)
- lung cancer (1)
- lymphocytes (1)
- lymphoid hyperplasia (1)
- malignancy (1)
- melanin (1)
- melanocytes (1)
- melanocytic markers (1)
- melanoma cells (1)
- melanomas (1)
- membrane proteins (1)
- mepacrine (1)
- metabolic disease (1)
- metastatic (1)
- methylation (1)
- moderate (1)
- mouse model (1)
- mucous membrane pemphigoid (1)
- multicenter (1)
- multiple sclerosis (1)
- mycosis fungoides (1)
- neurologic disease (1)
- nivolumab (1)
- oesophagogastroduodenoscopy (1)
- orofacial granulomatosis (1)
- outcomes research (1)
- outpatients (1)
- outreach (1)
- over-the-counter drugs (1)
- p53 (1)
- panel sequencing (1)
- papillary thyroid carcinoma (PTC) (1)
- patient access (1)
- patient preferences (1)
- pemphigus foliaceus (1)
- pemphigus vulgaris (1)
- perivascular epitheloid cell tumour (1)
- pityriasis rubra pilaris (1)
- plaque-type psoriasis (1)
- polymavirus (1)
- precision oncology (1)
- primary cutaneous follicular B-cell lymphoma (1)
- pseudolymphoma (1)
- pustular exanthema (1)
- quinacrine (1)
- quinine (1)
- radioiodine (1)
- real world data (1)
- resistance (1)
- responses (1)
- review (1)
- rhabdoid differentiation (1)
- rhabdoid melanoma (1)
- satellitosis (1)
- selpercatinib (1)
- skin (1)
- skin carcinogenesis (1)
- skin reactions (1)
- smoking (1)
- suppression (1)
- surgical and invasive medical procedures (1)
- survival (1)
- systemic sclerosis (1)
- targeted sequencing (1)
- tertiary lymphoid structures (1)
- thyroid carcinoma (TC) (1)
- transcription factors (1)
- treatment options (1)
- tumour immunology (1)
- utaneous adverse events (1)
- uveal melanoma (1)
- vesicles (1)
- virus (1)
Institute
- Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie (43)
- Medizinische Klinik und Poliklinik II (7)
- Pathologisches Institut (7)
- Comprehensive Cancer Center Mainfranken (3)
- Institut für Klinische Epidemiologie und Biometrie (2)
- Institut für Virologie und Immunbiologie (2)
- Kinderklinik und Poliklinik (2)
- Klinik und Poliklinik für Nuklearmedizin (2)
- Medizinische Klinik und Poliklinik I (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
Sonstige beteiligte Institutionen
Psoriasis is an immune-mediated systemic inflammatory disease that is not limited to the skin but may be associated with arthritis, cardiovascular diseases, metabolic syndrome including diabetes and obesity and, as identified more recently, non-alcoholic fatty liver disease (NAFLD) that occurs in approximately 50 % of all patients with psoriasis. NAFLD is characterized by accumulation of fat in hepatocytes in the absence of excessive alcohol consumption. Over the last two decades, NAFLD has developed to the most common chronic liver disease with an estimated prevalence of 25 % in the Western population. NAFLD ranges from non-inflammatory or bland hepatic steatosis to inflammation of hepatic tissue (non-alcoholic steatohepatitis, NASH) and consecutive liver fibrosis. It is controversial whether the underlying systemic inflammation of psoriasis is contributing to development of NAFLD or if comorbid diseases such as obesity enhance NAFLD development. Recent findings indicate that cytokine-mediated inflammation through TNFα, interleukin (IL)-6 and IL-17 might be the common link between psoriasis and NAFLD. Considering the shared inflammatory pathways, IL-17 pharmacological blockade, which is already well-established for psoriasis, may be a promising strategy to treat both psoriasis and NAFLD. Therefore, early detection of NAFLD and a better understanding of its pathophysiology in the context of the systemic inflammation in psoriasis is important with regard to individualized treatment approaches.
Cutaneous metastatic Crohn’s disease (MCD) is a rare but challenging dermatologic manifestation of Crohn’s disease. It is histologically defined as the presence of non-caseating granulomas at skin sites separated from and non-contiguous to the gastrointestinal tract. Cutaneous metastatic Crohn’s disease should be distinguished from the much more frequent contiguous cutaneous manifestations of Crohn’s disease that present at perianal or, less common, peristomal sites with direct extension from the intestine to the adjacent skin. Versatile clinical presentation and the fact that occurrence can predate the initial diagnosis of Crohn’s disease may lead to misdiagnosis, delayed treatment and underreporting. As case numbers are small and randomized controlled studies on management are lacking, the therapeutic approach remains challenging and is often unsatisfactory. We here performed a systematic literature search identifying 264 published pediatric and adult cases of MCD and additionally report three of our own cases. Our review summarizes clinical characteristics, putative etiopathology, histologic findings, differential diagnoses and treatment options for MCD.
Background
Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab. For avelumab-refractory patients, efficient and safe treatment options are lacking.
Methods
At three different sites in Germany, clinical and molecular data of patients with metastatic MCC being refractory to the PD-L1 inhibitor avelumab and who were later on treated with combined IPI/NIVO were retrospectively collected and evaluated.
Results
Five patients treated at three different academic sites in Germany were enrolled. Three out of five patients investigated for this report responded to combined IPI/NIVO according to RECIST 1.1. Combined immunotherapy was well tolerated without any grade II or III immune-related adverse events. Two out of three responders to IPI/NIVO received platinum-based chemotherapy in between avelumab and combined immunotherapy.
Conclusion
In this small retrospective study, we observed a high response rate and durable responses to subsequent combined immunotherapy with IPI/NIVO in avelumab-refractory metastatic MCC patients. In conclusion, our data suggest a promising activity of second- or third-line PD-1- plus CTLA-4-blockade in patients with anti-PD-L1-refractory MCC.